0001209191-18-052368.txt : 20180926
0001209191-18-052368.hdr.sgml : 20180926
20180926190017
ACCESSION NUMBER: 0001209191-18-052368
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180924
FILED AS OF DATE: 20180926
DATE AS OF CHANGE: 20180926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LANGE LOUIS G
CENTRAL INDEX KEY: 0001238401
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37833
FILM NUMBER: 181089146
MAIL ADDRESS:
STREET 1: 3172 PORTER DRIVE
CITY: PALO ALTO
STATE: CA
ZIP: 94034
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Audentes Therapeutics, Inc.
CENTRAL INDEX KEY: 0001628738
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461606174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
BUSINESS PHONE: 415-638-6556
MAIL ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-09-24
0
0001628738
Audentes Therapeutics, Inc.
BOLD
0001238401
LANGE LOUIS G
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR
SAN FRANCISCO
CA
94108
1
0
0
0
Common Stock
2018-09-24
4
S
0
19800
37.349
D
365999
D
Common Stock
2018-09-24
4
S
0
200
37.755
D
365799
D
Common Stock
2018-09-24
4
S
0
1000
37.2503
D
7555
I
By Adrienne M. MacMillan Revocable Trust
Common Stock
2018-09-24
4
S
0
1000
37.266
D
18678
I
By Amygdala Lange Trust
Common Stock
2018-09-24
4
S
0
1000
37.267
D
1558
I
By Lange Minor's Trust
Common Stock
2018-09-24
4
S
0
10000
37.4536
D
42343
I
By Asset Management Ventures Fund, L.P.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. The lowest price at which shares were sold was $36.72 and the highest price at which shares were sold was $37.71. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6) and (9) to this Form 4.
Represents the weighted average sale price. The lowest price at which shares were sold was $37.75 and the highest price at which shares were sold was $37.76.
Represents the weighted average sale price. The lowest price at which shares were sold was $36.84 and the highest price at which shares were sold was $37.61.
The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Represents the weighted average sale price. The lowest price at which shares were sold was $36.93 and the highest price at which shares were sold was $37.62.
The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
The reporting person's spouse is the trustee of the Lange Minor's Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Represents the weighted average sale price. The lowest price at which shares were sold was $37.00 and the highest price at which shares were sold was $37.675.
The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
/s/ Thomas Soloway as attorney-in-fact for Louis Lange, M.D., Ph.D.
2018-09-26